AMOEBA (EPA:AMEBA) - AMOEBA signs a distribution agreement with DREWO

Transparency directive : regulatory news

14/09/2017 17:40

PRESS RELEASE

               AMOEBA signs a distribution agreement with DREWO
                    Third distribution agreement in Europe

Lyon (France), Rome, September 14th, 2017 - AMOEBA (FR0011051598 - AMEBA),
producer of a biological biocide capable of eliminating bacterial risk in water
and wound care applications, announced today that it has signed a distribution
agreement for its BIOMEBA product with DREWO. This agreement is pending
marketing authorization (MA) in Italy.

The collaboration between DREWO and AMOEBA started in November 2015 with the
signature of a Letter of Intention (LOI). In August 2016, both companies
carried out a first field test in Italy for an industrial company in the
automotive sector. This test, still ongoing today, has confirmed the
effectiveness of BIOMEBA. Following this success, this car manufacturer wishes
to start a new field test on another industrial site before the end of the
year.

Meanwhile, a second test has started in January 2017 with a client of DREWO
from the food industry.

DREWO is the third European distributor to express its confidence towards
AMOEBA and its innovative technology through the signature of a distribution
agreement.

"Italy is very sensitive to environmental issues, we are looking to offer green
alternatives to our industrial customers. The BIOMEBA product, which we have
tested its effectiveness on industrial sites, is the biological solution that
we wish to offer to our customers." says Ernesto LATINI, Chief Executive
Officer of DREWO.

"We are very pleased to strengthen the commercial relationship with DREWO
through the signature of this distribution agreement. DREWO has a very
extensive customer portfolio specialized in the industrial sector which
represents a significant market for AMOEBA. " states Fabrice PLASSON, Chief
Executive Officer of AMOEBA.

About DREWO:

Since 1990 DREWO offers its customers an integrated service covering several
fields of expertise including chemical analysis and environmental impact
studies for wastewater management systems. The company also carries out
assessments of "legionella" risks in industrial cooling systems.
For more information: http://www.drewo.it

About AMOEBA:

AMOEBA group's objective is to become the global leader in eliminating
waterborne bacterial risk in water treatment and wound care applications. Our
solutions represent alternatives to chemical products widely used in the
cooling water treatment and the wound care market. In a global market for
chemical biocides estimated to be worth EUR 21 bn(1) AMOEBA is focusing on the
industrial cooling tower application estimated at EUR 1.7 bn(2). Similarly, in
a global wound care market estimated at EUR 15.2bn(3), AMOEBA is targeting the
chronic wound care market in the USA, estimated to be worth EUR 751 million(4).
The use of Willaertia magna C2c Maky in health care products will be subject to
FDA (Food and Drug Administration) clearance in the USA. AMOEBA's biological
biocide for water treatment, BIOMEBA, has not yet been granted marketing
authorization in the USA, Europe and Canada. AMOEBA is taking the required
regulatory steps to be granted marketing authorization in those regions for the
use of BIOMEBA in cooling water systems. Based in Chassieu (Lyon, France),
AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and
joined the CAC(r) Small index on 21st September 2015. More information on
www.amoeba-biocide.com.

(1) marketsandmarkets.com, "Wound Care Market by Product, Wound Type, End User
- Global Forecast to 2021," 2016.
(2): Amoéba data combined from the following sources: DRIRE 2013, Eurostat,
ARHIA 2013
(3) M. Diligence, "Wound Management: An $18.5 billion+ worldwide market in
2021," MedMarket Diligence, 10 June 2013. [Online]. Available:
http://blog.mediligence.com//2013/06/10/wound-management-an-18-5-billion-
worldwide-market-in-2021/. [Accessed 14 February 2017].
(4) BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017.

Contacts:

AMOEBA                                     ACTIFIN
Nathalie COMBROUSSE                        Ghislaine GASPARETTO
Marketing Communication Manager            Financial Communication
Tel. : +33 (0)4 81 09 18 15                Tel. : +33 (0)1 56 88 11 11
nathalie.combrousse@amoeba-biocide.com     ggasparetto@actifin.fr

DREWO
Ernesto LATINI
Chief Executive Officer
Tel. : +39 06 9006511
ernesto.latini@drewo.it

source : webdisclosure.com

AMOEBA's latest news

07/10/2024 17:45

AMOEBA (EPA:AMEBA) - AMOEBA signs a distribution agreement with DREWO

Transparency directive : regulatory news

AMOEBA's latest news

Other stories